Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099782 · ClinicalTrials.gov registry record · Phase 2
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 20
- Study locations
NCT06099782 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 147 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06099782, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Pembrolizumab (+) Berahyaluronidase alfa
Study Locations (20)
Region M. de Santiago
- FALP-UIDO ( Site 0401) - Santiago
- Oncovida ( Site 0403) - Santiago
- Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0407) - Santiago
- Bradfordhill-Clinical Area ( Site 0402) - Santiago
Florida
- Holy Cross Hospital-Clinical Research ( Site 0159) - Fort Lauderdale
- Mid Florida Hematology and Oncology Center ( Site 0113) - Orange City
Alabama
- Russell Medical ( Site 0160) - Alexander City
Alaska
- Alaska Oncology and Hematology ( Site 0121) - Anchorage
Arkansas
- Highlands Oncology Group-Research Department ( Site 0133) - Springdale
California
- Marin Cancer Care ( Site 0148) - Greenbrae
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0112) - Marietta
Washington
- Kadlec Clinic Hematology and Oncology ( Site 0103) - Kennewick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2023-12-26 |
| Est. Completion | 2026-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06099782
The ClinicalTrials.gov registry entry for NCT06099782 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06099782 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Region M. de Santiago, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06099782 about?
NCT06099782 is a clinical study titled "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)". The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be...
What is the current status of trial NCT06099782?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2023-12-26. Estimated completion is 2026-11-16.
What conditions does trial NCT06099782 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma.
What interventions are being tested in trial NCT06099782?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Pembrolizumab (+) Berahyaluronidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT06099782?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06099782 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.